When the susceptibility of C. albicans
clinical isolates recovered from CVV patients were tested, distinct growth inhibition endpoints were observed
(Table 2). The MIC range of the extract was 250 – 62.5 mg/l, with six of 14 isolates were susceptible to 125 mg/l.